{"name":"Abcuro, Inc.","slug":"abcuro-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ABC008","genericName":"ABC008","slug":"abc008","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ABC008","genericName":"ABC008","slug":"abc008","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPeEM5bk85dGpGS3ZYVzdoRE1iLXBmNmhTNlJqZ0pvb0RySzlnUlFFbjJzOHBhNWpGeGtaOFVNTTRURVdGS0JxYzFRZUw4RXJEby1QbF9hbHpnN2VGQU9KaVFQWXVwOGRyd0lHa3B4SEhSZ1hwdmNBU0MzMkZ1NmZ2aXZHUm9zb180RlBnYkM4R2VYdVdBT192bE9SMkNOYTZfbHFSalhmNDV2Zw?oc=5","date":"2026-02-25","type":"pipeline","source":"The Pharma Letter","summary":"Abcuro bullish on ulviprubart’s IBM prospects despite failure - The Pharma Letter","headline":"Abcuro bullish on ulviprubart’s IBM prospects despite failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5QYmZWNEJ4Ui0zRjFUbVA0dk9ZdGxtc2c3VFUyY1l0dmVKaWJRWmhCN3B5bFIwUGdPVDgtcWNlenk4LVJtTmZRTWZqV1RKT29taXFZ?oc=5","date":"2026-02-24","type":"trial","source":"FirstWord Pharma","summary":"Abcuro forging ahead with muscle weakness drug despite study miss - FirstWord Pharma","headline":"Abcuro forging ahead with muscle weakness drug despite study miss","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxQVnVndDVxZzZ0RkRGVTBkd2pTanhhSUQtTndjZ0pmUjBaUmZyUkpkSVpBQTRxSTBDNS13QXIxWjdvdi1sRnd0Tnczak5LZDV5ekp6ZUd2MzBoYlVHc3J3WnhiODNjNFdxMmk2bTZZUktDUnNSM0k0d2tRaktHcEQ4TVJ1b2JXVFd4eTBOWmRLMV9SQi11SUZ3N3VVX01oX2lSNkFweVR3S05wZlBHVFY5YjNCbXByc2hmWm1qdllXMnFQaXNGTHh6aXJ3Y0ZtSDhMY1dxLTVGbUJta3JUWkVJOUFneTJvbkNTaG1HNDJJc054WGxBVjFuZE9VYVJWNkdxVkVHRGx4bURlUGJ4bGllcUgwTmJMSmJPMVl0WFNXbjh0THZsNzR4R2FXOWNDMGwzX0o3V1BycE1GS3pqekNQMGd5OTFqZE9MWHJlNGVzSUUyWHBw?oc=5","date":"2025-12-08","type":"regulatory","source":"businesswire.com","summary":"Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting - businesswire.com","headline":"Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1TVW1fOFV2bmk5RnF5bXlFSkg2VWhOdnotUHBvSzh0Nm84aTg0V1dPaXl4cG5YLVpKbV81ZlItZkx3RWNrZWYtbFcxN1U0MFlnWllpUkh5bkpRd0kzZFJYMGMtTQ?oc=5","date":"2025-09-10","type":"pipeline","source":"PharmaTimes","summary":"George Eldridge - PharmaTimes","headline":"George Eldridge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQbEpMeWlJamx2WFdJeC1PUXV2S2ozeUdsSGx6VkZlZF85V005bmg4SWdRTER3aF8zdk5TWnVaNW1rQi1vOS1TNUZyYlpGeHlieEZZNngtcUhfTkJnQWpPbjhhOVdDQVZCdFl2aFB4LVExdUpIa3U2dnV5UFd1RWYtWWwtSi1Od2RyNUU1c0hSU3Y4LW1kWHFBYw?oc=5","date":"2025-02-14","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more - Medical Marketing and Media","headline":"Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPcEtxTHBvZjNHU0VIaGFweWRwS291TDA3YWdGSFIySzdLYVpTQmxtLW1fWHVDSW41T3l2bHZqSkU1X1hCOGh6N0o2bzN4SmxEdDA4dW00SlpYdENfSnhWNmtSdUFNOTJRWTE4dzNfYm1zQlVIQ3A2dlZOc3RDT09mZGxSSHFMM3c?oc=5","date":"2025-02-12","type":"pipeline","source":"pharmaphorum","summary":"Abcuro raises $200m to take muscle disease drug to market - pharmaphorum","headline":"Abcuro raises $200m to take muscle disease drug to market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE90QmZRQWFBbTFTOGdlYlpVcDd4N2hCYUhlVk5ZMUpSTGtxWExsSDc3bFBRWnRlZXFyc0M0NlFpN1o0emFEMXZSZUw3a19PX3MyT0lR?oc=5","date":"2025-02-12","type":"pipeline","source":"FirstWord Pharma","summary":"Abcuro draws $200M to push muscle weakness drug over the finish line - FirstWord Pharma","headline":"Abcuro draws $200M to push muscle weakness drug over the finish line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQOFFKZnNZQ1ctZEhXVWtXbUtoa0RQRDBxd194ZXVQRTZ1VFRjM3NvdGVuYVBnaDRuNGhrblhmMDZhcTcwV2Z2QXRuZThsNWNxdHRHbFdZOHg5OExlNS04R09qSmstUkdQNmhadFNOV05PMzBjcTRRVkhjX1RCWkNIRklfcWhJOWtWdS1EVkJMbDFqV2hlWHBZYkwtX0h0bFh3NFp5N3hQNVZCemxBamNoSzFYWUJFZWQycnJuUUpoZ1RGcXFxdXZ2M0pjcW1Lem1yX0tWVTJ2V1RGemFzNGhZTEFQeXRBVnh2MjVQTVRteWxpbTN0UlhIWS01S3Rzd0l6STVwdnZTdUZNTTI2?oc=5","date":"2025-01-06","type":"pipeline","source":"PR Newswire","summary":"Idiopathic Inflammatory Myositis Market Predicted to Show Positive Growth at a Tremendous CAGR of 21.1% by 2034 | DelveInsight - PR Newswire","headline":"Idiopathic Inflammatory Myositis Market Predicted to Show Positive Growth at a Tremendous CAGR of 21.1% by 2034 | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOUVFWcnAxRGRLdkUyX0JkSWdrVW92eUp4SDY2YjJRSWVBb01teEEyZmlqbEpoVEJURF9VMVFhczlUanRtNXBnWFBiUXJMR2o1UUpIQmlNcW5jQWM1UHM3S0RKcWgwdzVLTVZLTU9PUndBcXItN1lmWXdnNlNuZ1ZNUkNpRDdKVENxdS16eldPWTFwYlE?oc=5","date":"2024-06-26","type":"trial","source":"Pharmafile","summary":"Abcuro completes enrolment for phase 2/3 IBM treatment trial - Pharmafile","headline":"Abcuro completes enrolment for phase 2/3 IBM treatment trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9zX1QyZVU3b3JSNzZibUJkbG85R25JVk1ZQVN2X3R2d3A5WjMzMzNuX05hX19MaHQ4Vk5ZMkRtY2tzaVp0NGkxSXhBeWZlLW5OeldpcGNDa0FxNm5mUGxQQ19Fald5R1hQVkt6OUlPY0F4V2s?oc=5","date":"2023-08-17","type":"trial","source":"pharmaphorum","summary":"Abcuro raises $155m for KLRG1 drug trial - pharmaphorum","headline":"Abcuro raises $155m for KLRG1 drug trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}